Literature DB >> 11477311

Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion.

L M Shaw1, D W Holt, M Oellerich, B Meiser, T van Gelder.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11477311     DOI： 10.1097/00007691-200108000-00001

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN： 0163-4356            Impact factor:   3.681


× No keyword cloud information.
  44 in total

Review 1.  Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis.

Authors:  Kentaro Minagawa; Motohiro Yamamori; Yoshio Katayama; Toshimitsu Matsui
Journal:  Int J Hematol       Date:  2012-05-17       Impact factor: 2.490

Review 2.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  Pharmacokinetics of mycophenolic acid and determination of area under the curve by abbreviated sampling strategy in Chinese liver transplant recipients.

Authors:  Hao Chen; Chenghong Peng; Zhicheng Yu; Baiyong Shen; Xiaxing Deng; Weihua Qiu; Yue Fei; Chuan Shen; Guangwen Zhou; Weiping Yang; Hongwei Li
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

4.  Influence of clinical and demographic variables on mycophenolic acid pharmacokinetics in antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Melanie S Joy; Tandrea Hilliard; Yichun Hu; Susan L Hogan; Jinzhao Wang; Ronald J Falk; Philip C Smith
Journal:  Ann Pharmacother       Date:  2009-06-02       Impact factor: 3.154

5.  A limited sampling strategy for tacrolimus in renal transplant patients.

Authors:  Binu S Mathew; Denise H Fleming; Visalakshi Jeyaseelan; Sujith J Chandy; V M Annapandian; P K Subbanna; George T John
Journal:  Br J Clin Pharmacol       Date:  2008-06-28       Impact factor: 4.335

6.  Pharmacokinetics of free and total mycophenolic acid in adult lupus nephritis patients-implications for therapeutic drug monitoring.

Authors:  Paulina Łuszczyńska; Tomasz Pawiński; Paweł K Kunicki; Magdalena Durlik; Hanna Augustyniak-Bartosik; Magdalena Hurkacz
Journal:  Eur J Clin Pharmacol       Date:  2018-11-14       Impact factor: 2.953

7.  No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study.

Authors:  Olesja Rissling; Petra Glander; Pia Hambach; Marco Mai; Susanne Brakemeier; Daniela Klonower; Fabian Halleck; Eugenia Singer; Eva-Vanessa Schrezenmeier; Michael Dürr; Hans-Hellmut Neumayer; Klemens Budde
Journal:  Br J Clin Pharmacol       Date:  2015-07-14       Impact factor: 4.335

8.  Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.

Authors:  Brenda C M de Winter; Teun van Gelder; Ferdi Sombogaard; Leslie M Shaw; Reinier M van Hest; Ron A A Mathot
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-11-11       Impact factor: 2.745

9.  Mycophenolic acid area under the curve recovery time following rifampicin withdrawal.

Authors:  V M Annapandian; D H Fleming; B S Mathew; G T John
Journal:  Indian J Nephrol       Date:  2010-01

10.  Mycophenolic acid formulations in adult renal transplantation - update on efficacy and tolerability.

Authors:  Déla Golshayan; M Pascual; Bruno Vogt
Journal:  Ther Clin Risk Manag       Date:  2009-05-04       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.